Eli Lilly and CoChange company Symbol lookupSelect an option...LLY Eli Lilly and CoSCLXW Scilex Holding Equity Warrants Exp 11th Oct 2027 *W EXP 10/11/2027GMBL Esports Entertainment Group IncCFRX ContraFect CorpAAL American Airlines Group IncNVDA NVIDIA CorpAMD Advanced Micro Devices IncQQQ Invesco QQQ TrustAAPL Apple IncBBBY Bed Bath & Beyond IncGo
Eli Lilly and Company is engaged in a drug manufacturing business. The Company discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes products include Basaglar, Humalog, Humulin, Jardiance, Trajenta, and Trulicity. Its oncology products consist of Alimta, Cyramza, Erbitux, Retevmo, Tyvyt, and Verzenio. Its immunology products include Olumiant, Baricitinib, and Taltz. Its neuroscience products include Cymbalta, Emgality, and Zyprexa. Its other therapies consist of Bamlanivimab and etesevimab, Bebtelovimab, Cialis, and Forteo. It maintains special business groups to service wholesalers, pharmacy benefit managers, managed care organizations, group purchasing organizations, government and long-term care institutions, hospitals, and certain retail pharmacies. It manufactures and distributes its products through facilities in the United States, including Puerto Rico, and other countries. Its products are sold in about 120 countries.
|
|
|
|
| |
LLY's position in the Pharmaceuticals industry
| Industry Peers | BMY | ZTS | ITCI | RETA | |
|---|---|---|---|---|---|
Summary | |||||
| Company Profile | Eli Lilly and Company is engaged in a drug manufacturing business. The Company discovers, develops, manufactures, and markets products in the human pharmaceutical products segment. Its diabetes... | Bristol-Myers Squibb Company is a biopharmaceutical company. The Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical... Go to BMY summary | Zoetis Inc. is an animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices... Go to ZTS summary | Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused on the discovery, clinical development and commercialization of small molecule drugs that address underserved... Go to ITCI summary | Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on identifying, developing, and commercializing therapies. The Company is also focused on providing... Go to RETA summary |
| 52-Week Change | VS. INDUSTRY | 17.15% | -15.23% | 3.43% | 55.73% |
| Market Cap | VS. INDUSTRY | $155.6B | $77.1B | $4.6B | $1.5B |
| Beta | VS. INDUSTRY | 0.4 | 0.7 | 1.1 | 1.2 |
| Dividend Yield | VS. INDUSTRY | 3.12% | 0.91% | -- | -- |
| P/E (TTM, GAAP) | VS. INDUSTRY | 23.85x | 37.83x | -- | -- |
| Data as of | |||||
Fundamentals | |||||
| Total Revenue (TTM) | VS. INDUSTRY | $46.7B | $8.0B | $188.1M | $3.1M |
| Profit Margin | VS. INDUSTRY | 14.32% | 25.78% | -158.39% | -9,901.05% |
| Earnings Growth (5 year, GAAP) | VS. INDUSTRY | 3.27% | 20.99% | -- | -- |
| Revenue Growth (TTM) | VS. INDUSTRY | 2.79% | 5.13% | 166.50% | -77.09% |
| Data as of |
Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.